Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UT Southwestern Medical Center

Sites in Dallas, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1264
Shown on this page
12
Current sort
Recently updated
Campus scope
UT Southwestern Medical Center, Dallas, TX
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UT Southwestern Medical Center, Dallas, TX. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 841–852 of 1,264 matching trials with a site at UT Southwestern Medical Center, Dallas, TX.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting No phase listed Observational

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

NCT07673016
Status at this site: Recruiting
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma (UC), Hematuria, Upper Tract Urothelial Cancer
Interventions
Not listed
Lead sponsor
Convergent Genomics, Inc.
Network
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
21
States / cities
Oceanside, California • San Diego, California • San Jose, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Active, not recruiting Phase 2 Interventional

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

NCT02398773
Site status not listed — check the official record
View directory record Official record
Conditions
HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
25
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Recruiting Phase 2 Interventional

SPI-1005 in Adults Receiving Cochlear Implant

NCT06340633
Status at this site: Recruiting
View directory record Official record
Conditions
Hearing Loss, Cochlear Trauma
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Iowa City, Iowa • Columbus, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Active, not recruiting Phase 2 Interventional

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

NCT05966194
Site status not listed — check the official record
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT06498960
Site status not listed — check the official record
View directory record Official record
Conditions
Normal Pressure Hydrocephalus
Interventions
CereVasc eShunt System, VP Shunt
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
60 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Recruiting Not applicable Interventional

Recovery Through Inspiration, Support, and Empowerment

NCT07051200
Status at this site: Recruiting
View directory record Official record
Conditions
Suicidal Ideation, Suicide Attempt, Anxiety, Depression Disorders
Interventions
Peer Support Services Recovery
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 27 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Role of Sirolimus in Preventing Functional Decline in Older Adults

NCT05237687
Status at this site: Recruiting
View directory record Official record
Conditions
Aging
Interventions
Sirolimus
Drug
Lead sponsor
Irina Timofte
Other
Eligibility
65 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

MTOR Inhibitors in Older Adults

NCT06727305
Status at this site: Recruiting
View directory record Official record
Conditions
Aging
Interventions
Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet, Everolimus 0.5 MG Oral Tablet, Everolimus 1 MG Oral Tablet, Everolimus 2 MG Oral Tablet
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Not yet recruiting Phase 2 Interventional

Erlotinib for Hepatocellular Carcinoma Chemoprevention

NCT04172779
Site status not listed — check the official record
View directory record Official record
Conditions
Cirrhosis, Liver, Advanced Liver Fibrosis
Interventions
erlotinib hydrochloride, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

RESTORE: An RCT to Evaluate the Efficacy of the Revi System

NCT06217328
Site status not listed — check the official record
View directory record Official record
Conditions
Urinary Urge Incontinence
Interventions
Revi System Treatment, Revi System - Delayed Activation
Device
Lead sponsor
BlueWind Medical
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
19
States / cities
Tucson, Arizona • Pasadena, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
Status at this site: Recruiting
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 7, 2026, 11:30 AM EST
Recruiting Phase 2 Interventional

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

NCT05401097
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biopsy, Enasidenib, Ivosidenib, Venetoclax
Drug · Procedure
Lead sponsor
Alice Mims
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 7, 2026, 11:30 AM EST

About this UT Southwestern Medical Center institution page

What this page lists
ClinicalTrials.gov records that list UT Southwestern Medical Center in Dallas, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.